Patents by Inventor Rita Mancini

Rita Mancini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MiRNAs for treatment and in vitro diagnosis of drug resistant tumors
    Patent number: 11492671
    Abstract: miRNAs for in vitro diagnosis of resistance of tumors to BRAF/MEK pathway (also named as MAPK 5 pathway) inhibiting drugs and for treatment of tumors which are treated with said drugs, such as melanoma, by stimulating or inhibiting the expression of down-regulated or up-regulated miRNAs, respectively.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: November 8, 2022
    Assignees: ISTITUTI FISIOTERAPICI OSPITALIERI, ISTITUTO NAZIONALE TUMORI I.R.C.C.S. “FONDAZIONE G. PASCALE”, UNIVERSITA' DEGLI STUDI DI ROMA “LA SAPIENZA”
    Inventors: Gennaro Ciliberto, Paolo Antonio Ascierto, Luigi Fattore, Gerardo Botti, Rita Mancini
  • MIRNAS FOR TREATMENT AND IN VITRO DIAGNOSIS OF DRUG RESISTANT TUMORS
    Publication number: 20210147945
    Abstract: miRNAs for in vitro diagnosis of resistance of tumors to BRAF/MEK pathway (also named as MAPK 5 pathway) inhibiting drugs and for treatment of tumors which are treated with said drugs, such as melanoma, by stimulating or inhibiting the expression of down-regulated or up-regulated miRNAs, respectively.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 20, 2021
    Inventors: Gennaro CILIBERTO, Paolo Antonio ASCIERTO, Luigi FATTORE, Gerardo BOTTI, Rita MANCINI
  • Immunotherapy against ErbB-3 receptor
    Patent number: 10745459
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 18, 2020
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • IMMUNOTHERAPY AGAINST ERBB-3 RECEPTOR
    Publication number: 20170342123
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Application
    Filed: June 1, 2017
    Publication date: November 30, 2017
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Immunotherapy against ErbB-3 receptor
    Patent number: 9688738
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 27, 2017
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • IMMUNOTHERAPY AGAINST ERBB-3 RECEPTOR
    Publication number: 20140017259
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Application
    Filed: November 2, 2011
    Publication date: January 16, 2014
    Applicant: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Bag made of recycled components
    Publication number: 20120141047
    Abstract: The invention relates to a bag (10) comprising at least one floppy containment portion. Said containment portion consists of a recycled airbag (11).
    Type: Application
    Filed: December 1, 2010
    Publication date: June 7, 2012
    Applicant: MASALA snc DI MANCINI RITA & CARLA
    Inventor: Rita Mancini